middl
east
respiratori
syndrom
coronaviru
merscov
novel
human
coronaviru
caus
outbreak
sarslik
ill
middl
east
consid
threat
global
public
health
review
discuss
challeng
identifi
sourc
fatal
viru
develop
effect
safe
antimerscov
vaccin
therapeut
order
control
spread
combat
futur
pandem
septemb
dr
ali
moh
zaki
virologist
dr
fakeeh
hospit
jeddah
saudi
arabia
first
report
program
monitor
emerg
diseas
promedmail
novel
coronaviru
ncov
isol
lung
male
patient
acut
pneumonia
acut
renal
failur
septemb
world
health
organ
inform
unit
kingdom
uk
male
qatari
nation
travel
histori
saudi
arabia
qatar
show
symptom
ncov
infect
novemb
viru
identifi
novel
betacoronaviru
closest
rel
bat
coronavirus
dr
ron
fouchier
group
erasmu
medic
center
rotterdam
netherland
thu
term
hcovemc
may
viru
renam
middl
east
respiratori
syndrom
mer
coronaviru
merscov
coronaviru
studi
group
intern
committe
taxonomi
virus
term
adopt
june
inform
confirm
case
includ
death
case
fatal
rate
four
countri
middl
east
saudi
arabia
jordan
qatar
unit
arab
emir
three
countri
europ
franc
itali
unit
kingdom
one
countri
africa
tunisia
tabl
patient
report
europ
origin
infect
travel
middl
east
becam
ill
return
europ
other
middl
east
close
contact
laboratoryconfirm
probabl
case
becam
infect
limit
persontoperson
transmiss
far
eight
merscov
cluster
report
largest
cluster
link
one
healthcar
facil
alahsa
saudi
arabia
consist
patient
includ
death
two
patient
healthcar
provid
infect
care
patient
merscov
infect
evid
strongli
suggest
humantohuman
transmiss
involv
differ
mode
droplet
contact
transmiss
although
effici
humantohuman
transmiss
merscov
lower
sever
acut
respiratori
syndrom
sar
coronaviru
sarscov
howev
merscov
may
gain
increas
humantohuman
transmiss
adapt
evolut
human
asyet
unknown
intermedi
host
eventu
caus
global
pandem
like
one
caus
sarscov
may
sixtysixth
world
health
assembl
geneva
switzerland
dr
margaret
chan
directorgener
point
novel
coronaviru
threat
entir
world
still
know
viru
hide
natur
peopl
becom
infect
june
obama
administr
design
merscov
threat
public
health
nation
secur
gave
offici
author
fasttrack
approv
test
treatment
merscov
dr
kathleen
sebeliu
secretari
depart
health
human
servic
unit
state
made
design
allow
us
food
drug
administr
fda
quickli
approv
product
accept
emerg
use
applic
eua
midoctob
year
two
million
muslim
undertak
hajj
annual
pilgrimag
mecca
remain
confin
geograph
area
fiveday
period
medic
author
saudi
arabia
taken
immedi
step
implement
control
measur
fear
potenti
merscov
pandem
result
event
includ
advis
wear
face
mask
overcrowd
area
therefor
research
need
take
appropri
step
identifi
sourc
merscov
track
intermedi
host
develop
strategi
control
spread
goal
also
bring
number
challeng
first
challeng
confront
research
identifi
sourc
merscov
genet
know
viru
close
relat
tylonycteri
bat
cov
tybatcov
pipistrellu
bat
cov
pibatcov
bat
hong
kong
howev
molecular
clock
analysi
suggest
bat
virus
unlik
direct
ancestor
merscov
merscov
use
evolutionarili
conserv
dipeptidyl
peptidas
function
receptor
enter
target
cell
via
plasma
endosom
membran
fusion
replic
host
cell
similar
way
sarscov
fig
infect
variou
mammalian
cell
line
primat
porcin
bat
rabbit
cell
suggest
merscov
may
broad
speci
tropism
report
merscov
case
note
histori
contact
anim
camel
goat
suggest
merscov
may
jump
bat
anim
infect
human
howev
anim
reservoir
intermedi
host
still
identifi
significantli
hinder
develop
strategi
control
emerg
infecti
diseas
combat
potenti
pandem
mer
control
mer
must
develop
effect
safe
vaccin
constitut
second
challeng
research
howev
problem
encount
develop
sar
vaccin
revisit
mer
vaccin
design
inactiv
virusbas
dnabas
viral
vectorbas
vaccin
candid
could
induc
immunopatholog
immunoenhanc
patholog
rais
concern
safeti
sar
vaccin
previou
studi
shown
sar
vaccin
candid
base
receptorbind
domain
rbd
subunit
sarscov
spike
protein
effect
safer
abovement
vaccin
candid
compar
sequenc
spike
protein
sarscov
merscov
predict
acid
fragment
residu
subunit
merscov
contain
rbd
strongli
believ
rbd
merscov
spike
protein
therefor
import
target
develop
mer
vaccin
recent
chan
et
al
report
sera
convalesc
sar
patient
contain
antibodi
could
crossreact
crossneutr
merscov
rais
hope
peopl
histori
sarscov
infect
might
suscept
merscov
infect
howev
studi
demonstr
epitop
elicit
crossreact
antibodi
may
locat
rbd
sarscov
protein
thu
doubt
whether
antibodi
realli
role
crossprotect
merscov
date
effect
antivir
therapeut
merscov
discov
clinic
manag
mainli
support
place
emphasi
organ
support
respiratori
renal
failur
case
acut
respiratori
failur
use
extracorpor
membran
oxygen
ecmo
expect
improv
surviv
rate
significantli
sever
nonspecif
antivir
drug
ribavirin
lopinavir
type
ifn
use
treat
sar
tabl
cumul
number
mer
case
death
june
middl
east
saudi
arabia
jordan
qatar
unit
arab
emir
uae
europ
unit
kingdom
uk
franc
itali
africa
tunisia
total
although
actual
efficaci
patient
still
unclear
ifna
shown
inhibit
vitro
merscov
replic
cell
unknown
whether
work
vivo
thought
cytokin
storm
potenti
fatal
immun
reaction
character
massiv
releas
proinflammatori
cytokin
respons
death
patient
infect
highli
pathogen
avian
influenza
viru
sarscov
therefor
immunosuppress
immunomodulatori
drug
diminish
inflamm
infect
expect
therapeut
benefit
howev
whether
immunosuppress
drug
use
treat
mer
patient
debat
first
report
yet
shown
cytokin
storm
inde
respons
death
mer
patient
second
cell
host
respons
infect
merscov
much
differ
sarscov
infect
yuen
colleagu
believ
corticosteroid
consid
treat
mer
particularli
sinc
patient
sever
pneumonia
respiratori
failur
could
support
ecmo
cytokin
storm
similar
hiv
sarscov
merscov
enter
target
cell
proteinmedi
membran
fusion
fig
therefor
subunit
merscov
protein
may
serv
target
develop
merscov
fusion
inhibitor
earli
jiang
et
al
wild
et
al
found
peptid
deriv
domain
potent
activ
approv
us
fda
treatment
hivinfect
patient
fail
respond
current
antiretrovir
drug
jiang
colleagu
identifi
antisarscov
peptid
sarscov
protein
subunit
domain
similar
approach
could
also
use
identifi
antimerscov
peptid
differ
hivaid
treatment
regimen
need
longterm
inject
merscov
fusion
inhibitorbas
therapi
would
requir
regimen
day
onset
merscov
infect
save
patient
live
conclus
merscov
origin
caus
outbreak
sarslik
ill
middl
east
consid
threat
global
public
health
humantohuman
transmiss
far
limit
seriou
concern
pandem
potenti
rais
therefor
research
must
take
immedi
step
identifi
sourc
fatal
viru
develop
effect
safe
antimerscov
vaccin
therapeut
order
control
spread
combat
futur
pandem
fig
life
cycl
merscov
merscov
first
bind
via
protein
receptor
target
cell
releas
rna
genom
plasma
endosom
membran
fusion
target
cell
transcript
translat
new
genom
rna
viral
protein
assembl
virion
transport
via
vesicl
releas
host
cell
way
similar
sarscov
